Cargando…

MYL6B, a myosin light chain, promotes MDM2-mediated p53 degradation and drives HCC development

BACKGROUND: Identification of novel MDM2 or p53 binding proteins may reveal undefined oncogenes, tumor suppressors, signaling pathways and possible treatment targets. METHODS: By means of immunoprecipitation and Mass Spectrometry analysis, we aimed to identify novel regulators of the MDM2-p53 pathwa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Xingwang, Wang, Xueyan, Liao, Weijia, Fei, Ran, Wu, Nan, Cong, Xu, Chen, Qian, Wei, Lai, Wang, Yu, Chen, Hongsong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5812214/ https://www.ncbi.nlm.nih.gov/pubmed/29439719 http://dx.doi.org/10.1186/s13046-018-0693-7

Ejemplares similares

Dynamic Regulation of Vascular Myosin Light Chain (MYL9) with Injury and Aging
por: Shehadeh, Lina A., et al.
Publicado: (2011)

The landscape of prognostic and immunological role of myosin light chain 9 (MYL9) in human tumors
por: Lv, Minghe, et al.
Publicado: (2021)

Human cardiac myosin light chain 4 (MYL4) mosaic expression patterns vary by sex
por: Wang, Tony Y., et al.
Publicado: (2019)

A mutation in the atrial-specific myosin light chain gene (MYL4) causes familial atrial fibrillation
por: Orr, Nathan, et al.
Publicado: (2016)

Sarcomeric perturbations of myosin motors lead to dilated cardiomyopathy in genetically modified MYL2 mice
por: Yuan, Chen-Ching, et al.
Publicado: (2018)

Serum Response Factor (SRF) Drives the Transcriptional Upregulation of the MDM4 Oncogene in HCC
por: Pellegrino, Rossella, et al.
Publicado: (2021)

Molecular basis of force-pCa relation in MYL2 cardiomyopathy mice: Role of the super-relaxed state of myosin
por: Yuan, Chen-Ching, et al.
Publicado: (2022)

Predictive Models for HCC Prognosis, Recurrence Risk, and Immune Infiltration Based on Two Exosomal Genes: MYL6B and THOC2
por: Zhu, Jinyu, et al.
Publicado: (2021)

Dysfunction of Myosin Light‐Chain 4 (MYL4) Leads to Heritable Atrial Cardiomyopathy With Electrical, Contractile, and Structural Components: Evidence From Genetically‐Engineered Rats
por: Peng, Wenhui, et al.
Publicado: (2017)

FOXP3 expression in FOXP3(+) tumor cells promotes hepatocellular cells metastasis
por: Zhang, Henghui, et al.
Publicado: (2020)

Analysis of myosin genes in HNSCC and identify MYL1 as a specific poor prognostic biomarker, promotes tumor metastasis and correlates with tumor immune infiltration in HNSCC
por: Li, Ce, et al.
Publicado: (2023)

MYL6B drives the capabilities of proliferation, invasion, and migration in rectal adenocarcinoma through the EMT process
por: Li, Jin-Liang, et al.
Publicado: (2020)

MYBPC2 and MYL1 as Significant Gene Markers for Rhabdomyosarcoma
por: Chen, Zihang, et al.
Publicado: (2021)

MYL2 as a potential predictive biomarker for rhabdomyosarcoma
por: Wang, Junning, et al.
Publicado: (2021)

Erratum to “MYL6B drives the capabilities of proliferation, invasion, and migration in rectal adenocarcinoma through the EMT process”
por: Wang, Zai-Qiu, et al.
Publicado: (2020)

MYL-1402O: A Bevacizumab Biosimilar
por: Lee, Arnold
Publicado: (2021)

XPC promotes MDM2-mediated degradation of the p53 tumor suppressor
por: Krzeszinski, Jing Yan, et al.
Publicado: (2014)

P464: PULSE DOSING OF POTENT AND SELECTIVE HETEROBIFUNCTIONAL MDM2 DEGRADER KT-253 DRIVES TUMOR REGRESSION AND DEMONSTRATES DIFFERENTIATED PHARMACOLOGY COMPARED TO P53/MDM2 SMALL MOLECULE INHIBITORS.
por: Schalm, Stefanie, et al.
Publicado: (2023)

Correction to: MYL-1402O: A Bevacizumab Biosimilar
por: Lee, Arnold
Publicado: (2022)

Insight Into the Binding Mechanism of p53/pDIQ-MDMX/MDM2 With the Interaction Entropy Method
por: Li, Mengxin, et al.
Publicado: (2019)

The MDM2-p53 pathway revisited
por: Nag, Subhasree, et al.
Publicado: (2013)

LINC01468 drives NAFLD-HCC progression through CUL4A-linked degradation of SHIP2
por: Wang, Hongquan, et al.
Publicado: (2022)

MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation
por: Hirose, Mitsuaki, et al.
Publicado: (2014)

Molecular Mechanism of MYL4 Regulation of Skeletal Muscle Development in Pigs
por: Xu, Xueli, et al.
Publicado: (2023)

Silencing the Myosin Regulatory Light Chain Gene sqh Reduces Cold Hardiness in Ophraella communa LeSage (Coleoptera: Chrysomelidae)
por: Tian, Zhenqi, et al.
Publicado: (2020)

Energetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 Interaction
por: Thayer, Kelly M., et al.
Publicado: (2016)

Regulation of p53: a collaboration between Mdm2 and MdmX
por: Pei, Dongsheng, et al.
Publicado: (2012)

Regulation of kidney development by the Mdm2/Mdm4–p53 axis
por: El-Dahr, Samir, et al.
Publicado: (2017)

Ubiquitin receptors play redundant roles in the proteasomal degradation of the p53 repressor MDM2
por: Sparks, Alison, et al.
Publicado: (2022)

Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
por: Mrkvová, Zuzana, et al.
Publicado: (2019)

Expression and prognostic significance of MYL9 in esophageal squamous cell carcinoma
por: Wang, Jian-Hua, et al.
Publicado: (2017)

Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma
por: Matsushita, Katsunori, et al.
Publicado: (2021)

Elevated Myl9 reflects the Myl9-containing microthrombi in SARS-CoV-2–induced lung exudative vasculitis and predicts COVID-19 severity
por: Iwamura, Chiaki, et al.
Publicado: (2022)

ADCK2 Knockdown Affects the Migration of Melanoma Cells via MYL6
por: Vierthaler, Marlene, et al.
Publicado: (2022)

Detection of P53 and Mdm2 in vitiligo
por: Wiwanitkit, Viroj
Publicado: (2013)

Evolution of the p53-MDM2 pathway
por: Åberg, Emma, et al.
Publicado: (2017)

Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule
por: Grinkevich, Vera V., et al.
Publicado: (2022)

The role of MDM2–p53 axis dysfunction in the hepatocellular carcinoma transformation
por: Cao, Hui, et al.
Publicado: (2020)

ODP281 JDP2 Interacts with MDM2 and Decreases MDM2-Mediated p53 Repression
por: Yang, William, et al.
Publicado: (2022)

Wild-type and cancer-related p53 proteins are preferentially degraded by MDM2 as dimers rather than tetramers
por: Katz, Chen, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_thus34u0g1nrt86l7f199b7ad7